Current Edition

Custopharm

Hikma bolsters injectables franchise with $425M deal for Custopharm, but FTC review looms

Generics giant Hikma is boosting its injectables business to nearly 130 products in the U.S. by way of dealmaking. For $375 million upfront and another …

Continue Reading →